Literature DB >> 29685474

The Evaluation and Management of Rocky Mountain Spotted Fever in the Emergency Department: a Review of the Literature.

Michael Gottlieb1, Brit Long2, Alex Koyfman3.   

Abstract

BACKGROUND: Rocky Mountain spotted fever (RMSF) is potentially deadly and can present subtly with signs and symptoms overlapping with other clinical conditions. Delayed diagnosis can be fatal.
OBJECTIVE: This review provides an evidence-based summary of the current data for the evaluation and management of RMSF in the emergency department. DISCUSSION: RMSF occurs through transmission of Rickettsia rickettsii by an infected tick. Exposure in the United States occurs most commonly from April to September, and high-risk locations include wooded, shrubby, or grassy areas. Approximately half of patients with infection do not recall tick exposure. Symptoms can include fever, headache, photophobia, malaise, myalgias, and a petechial rash that begins on the wrists and ankles and spreads to the trunk. Rash may not occur in ≤15% of patients, and the classic triad of fever, headache, and rash is also not definitive. Laboratory evaluation may demonstrate hyponatremia, anemia, thrombocytopenia, abnormal liver enzymes, and elevated coagulation tests. Antibody testing can be helpful, but these results are not typically available to the emergency clinician. Doxycycline is the treatment of choice in adults, children, and pregnant patients. Patients should be advised about prevention strategies and effective techniques for removing ticks.
CONCLUSIONS: RMSF is a potentially deadly disease that requires prompt recognition and management. Focused history, physical examination, and testing are important in the diagnosis of this disease. Understanding the clinical features, diagnostic tools, and proper treatment can assist emergency clinicians in the management of RMSF. Published by Elsevier Inc.

Entities:  

Keywords:  Rocky Mountain spotted fever; fever; petechiae; rash; tick; tick-borne; vasculitis

Mesh:

Substances:

Year:  2018        PMID: 29685474     DOI: 10.1016/j.jemermed.2018.02.043

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  5 in total

1.  Impact of a Severe Rocky Mountain Spotted Fever Case on Treatment Practices at an Academic Institution Within a Nonendemic Area.

Authors:  Conrad Krawiec; Gary D Ceneviva; Shouhao Zhou; Neal J Thomas
Journal:  Wilderness Environ Med       Date:  2021-08-12       Impact factor: 1.518

2.  Rickettsia rickettsii Whole-Cell Antigens Offer Protection against Rocky Mountain Spotted Fever in the Canine Host.

Authors:  Andy Alhassan; Huitao Liu; Jodi McGill; Argine Cerezo; Laxmi U M R Jakkula; Arathy D S Nair; Emma Winkley; Sally Olson; Denver Marlow; Abha Sahni; Hema P Narra; Sanjeev Sahni; Jamie Henningson; Roman R Ganta
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

Review 3.  A forty-year review of Rocky Mountain spotted fever cases in California shows clinical and epidemiologic changes.

Authors:  Anne M Kjemtrup; Kerry Padgett; Christopher D Paddock; Sharon Messenger; Jill K Hacker; Tina Feiszli; Michael Melgar; Marco E Metzger; Renjie Hu; Vicki L Kramer
Journal:  PLoS Negl Trop Dis       Date:  2022-09-15

4.  Epidemiology and Clinical Features of Rocky Mountain Spotted Fever from Enhanced Surveillance, Sonora, Mexico: 2015-2018.

Authors:  Diego I Álvarez-López; Estefanía Ochoa-Mora; Kristen Nichols Heitman; Alison M Binder; Gerardo Álvarez-Hernández; Paige A Armstrong
Journal:  Am J Trop Med Hyg       Date:  2021-01       Impact factor: 3.707

5.  Long term neurologic sequelae in a Mexican rocky mountain spotted fever case.

Authors:  Karla Rossanet Dzul-Rosado; Cesar Lugo-Caballero; Alejandra Salcedo-Parra; Raymundo Daniel López-Soto; Álvaro A Faccini-Martínez
Journal:  Braz J Infect Dis       Date:  2019-05-16       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.